PCA3 and prostate carcinoma: For instance, Salameh et al. demonstrated that PCA3 lncRNA, a well-characterized tumor suppressor in prostate cancer, binds its sense partner PRUNE2, facilitating ADAR-mediated A-to-I RNA editing.